A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Clinical trial NCT05044234 · TERMINATED
Trial details
- NCT number
- NCT05044234
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-16
- Primary completion
- 2022-11-30
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.